TGFB1 and Feingold syndrome type 2: In the mouse model for Feingold syndrome type 2, using genetic and pharmacological interventions, we have demonstrated that the upregulation in TGF-β signaling due to derepression of Tgfbr2, a direct target of multiple miR-17-92 miRNAs, plays the causal role.